Real-life Use of Bexarotene for T-cell Cutaneous Lymphoma Management: Efficacy and Tolerance with Low Doses
DOI:
https://doi.org/10.2340/actadv.v102.718Keywords:
bexarotene, T-cell cutaneous lymphoma, mycosis fungoides, Sezary syndrome, depressionAbstract
Abstract is missing (Short communication)
Downloads
References
Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 2019; 133: 1703-1714.
https://doi.org/10.1182/blood-2018-11-881268 DOI: https://doi.org/10.1182/blood-2018-11-881268
Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001; 19: 2456-2471.
https://doi.org/10.1200/JCO.2001.19.9.2456 DOI: https://doi.org/10.1200/JCO.2001.19.9.2456
Sokolowska-Wojdylo M, Florek A, Zaucha JM, Chmielowska E, Giza A, Knopinska-Posluszny W, et al. Polish Lymphoma Research Group experience with bexarotene in the treatment of cutaneous t-cell lymphoma. Am J Ther 2016; 23: e749-756.
https://doi.org/10.1097/MJT.0000000000000056 DOI: https://doi.org/10.1097/MJT.0000000000000056
Quereux G, Saint-Jean M, Peuvrel L, Brocard A, Knol AC, Dreno B. Bexarotene in cutaneous T-cell lymphoma: third retrospective study of long-term cohort and review of the literature. Expert Opin Pharmacother 2013; 14: 1711-1721.
https://doi.org/10.1517/14656566.2013.810718 DOI: https://doi.org/10.1517/14656566.2013.810718
Väkevä L, Ranki A, Hahtola S. Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland. Acta Derm Venereol 2012; 92: 258-263.
https://doi.org/10.2340/00015555-1359 DOI: https://doi.org/10.2340/00015555-1359
Abbott RA, Whittaker SJ, Morris SL, Russell-Jones R, Hung T, Bashir SJ, et al. Bexarotene therapy for mycosis fungoides and Sezary syndrome. Br J Dermatol 2009; 160: 1299-1307.
https://doi.org/10.1111/j.1365-2133.2009.09037.x DOI: https://doi.org/10.1111/j.1365-2133.2009.09037.x
Roche Gamon E, Perez Ferriols A, Vilata Corell JJ, Alegre de Miquel V. [Mycosis fungoid treated with oral bexarotene: study of 13 cases]. Med Clin (Barc) 2007; 129: 677 (in Spanish).
https://doi.org/10.1157/13112095 DOI: https://doi.org/10.1157/13112095
Fujimura T, Sato Y, Tanita K, Amagai R, Shimauchi T, Ogata D, et al. Case series of cutaneous T-cell lymphomas treated with bexarotene-based therapy. J Dermatol 2020; 47: 636-640.
https://doi.org/10.1111/1346-8138.15322 DOI: https://doi.org/10.1111/1346-8138.15322
Gniadecki R, Assaf C, Bagot M, Dummer R, Duvic M, Knobler R, et al. The optimal use of bexarotene in cutaneous T-cell lymphoma. Br J Dermatol 2007; 157: 433-440.
https://doi.org/10.1111/j.1365-2133.2007.07975.x DOI: https://doi.org/10.1111/j.1365-2133.2007.07975.x
Published
How to Cite
License
Copyright (c) 2022 Jacques Rouanet, Ines Joulie, Celine Lambert, Michel D'Incan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
